...
首页> 外文期刊>International Journal of Pharmaceutics >Two glycine containing 2-chloroethylnitrosoureas--a comparative study on some physicochemical properties, in vivo antimelanomic effects and immunomodulatory properties.
【24h】

Two glycine containing 2-chloroethylnitrosoureas--a comparative study on some physicochemical properties, in vivo antimelanomic effects and immunomodulatory properties.

机译:两种含有2-氯乙基亚硝基脲的甘氨酸-一些理化性质,体内血液变迁效应和免疫调节性质的比较研究。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Physicochemical properties such as alkylating and carbamoylating activity and in vivo antimelanomic effects against B16 melanoma of the spin labeled (nitroxyl free radical containing) glycine nitrosourea (SLCNUgly) and its nonlabeled analogue (ChCNUgly), synthesized in our laboratory are studied and compared to those of antitumour drug 3-cyclohexyl-1-(2-chloroethyl)-1-nitrosourea (CCNU). We have demonstrated that introducing of glycine moiety in the nitrosourea structure in practice does not affect either alkylating or carbamoylating activity. On the other hand replacement of cyclohexyl moiety in ChCNUgly structure with nitroxyl free radical leads to a decrease in carbamoylating activity and an increase in alkylating activity. Compound ChCNUgly showed in vivo a higher antimelanomic activity against B16 melanoma in comparison with CCNU and SLCNUgly. It completely inhibited B16 melanoma growth (TGI=100%) at a dose 64.0 mg/kg. Moreover, we established that joint i.p. application in normal mice of SLCNUgly plus a new immunostimulator (C3bgp) formerly isolated in our laboratory led to a 75% restoration in immune function with respect to antibody production measured by Jerne hemolytic plaque assay. In contrast, no immunostimulation was found after joint application of C3bgp plus ChCNUgly or CCNU at the same experimental conditions. Based on these preliminary results, a possibility for developing of new combination immunochemotherapy schemes for treatment of human cancers is discussed.
机译:研究了在我们实验室中合成的自旋标记的(含硝基氧自由基的)甘氨酸亚硝基脲(SLCNUgly)及其未标记的类似物(ChCNUgly)对B16黑色素瘤的理化性质,如烷基化和氨基甲酰化活性以及体内抗代谢活性的影响。抗肿瘤药3-cyclohexyl-1-(2-chloroethyl)-1-nitrosourea(CCNU)。我们已经证明,实际上在亚硝基脲结构中引入甘氨酸部分不影响烷基化或氨基甲酰化活性。另一方面,用硝基氧基取代ChCNUgly结构中的环己基部分导致氨基甲酰化活性降低和烷基化活性提高。与CCNU和SLCNUgly相比,化合物ChCNUgly在体内显示出更高的抗B16黑色素瘤的抗癌活性。它以64.0 mg / kg的剂量完全抑制了B16黑色素瘤的生长(TGI = 100%)。此外,我们建立了联合i.p.在SLCNUgly的正常小鼠中加上先前在我们实验室中分离出的新型免疫刺激剂(C3bgp)的应用,相对于通过Jerne溶血斑检测测定的抗体产生,免疫功能恢复了75%。相反,在相同的实验条件下联合应用C3bgp加ChCNUgly或CCNU后,未发现免疫刺激作用。基于这些初步结果,讨论了开发用于治疗人类癌症的新的组合免疫化学疗法方案的可能性。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号